RTID-08. A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA (ndGBM OR rGBM)

BACKGROUND: GBM is the most common and most aggressive primary brain tumor with poor prognosis and median overall survival (mOS) of patients with ndGBM and rGBM being 15 vs 5-7 months, respectively. Selinexor is a first-in class, oral, selective nuclear export inhibitor which forces nuclear retentio...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Wen, Patrick, Odia, Yazmin, Mehta, Minesh, Goldlust, Samuel, Tamir, Sharon, Shacham, Sharon, Wang, Hongwei, Sheehan, Heidi, Li, Kai
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Randomized Trials in Development
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651017/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.813
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk